Groups that represent 340B hospitals are defending the drug discount program and their role in it in response to a Wall Street Journal article Tuesday that raised questions about how some hospitals qualify for and use the program.
The nation’s
…
Articles by : Tom Mirga, Editor at Large
Drug manufacturer Viatris will give 340B covered entities credits on requests for purchases of dozens of NDCs at higher than 340B ceiling price during the first 11 days of August, the company says in a notice on the U.S. Health
…Breaking News
Wall Street Journal Says Its Investigation of 340B Hospitals Raises Questions about Program’s Growth and Purpose
A growing number of hospitals that do not qualify for 340B drug discounts as disproportionate share hospitals are enrolling instead under less demanding criteria for rural referral centers—including nationally prominent urban hospitals in metro Boston, Chicago, and Cleveland, The Wall
…
U.S. House and Senate appropriations committees want federal healthcare officials to brief them by April “on actions taken to safeguard covered entities’ lawful access to discounted drugs” under the 340B program.
The directive to the Health Resources and Services Administration
…
Biopharmaceutical manufacturer Amgen yesterday became the 10th drug manufacturer to sue the federal government over the government’s position that the 340B statute requires drug companies to provide 340B-priced drugs to multiple contract pharmacies without conditions.
California-based Amgen filed suit
…
Drug manufacturer Merck is providing refunds for charges above 340B ceiling prices on 23 NDCs purchased during Q4 2019, Q3 2021, and Q2 2022.
The U.S. Health Resources and Services Administration posted Merck’s Nov. 21 notice about the repayments on
…
Thirty-five percent of drugs paid for by Medicare Part B in 2021 were administered in 340B hospital outpatient departments, up from 19% in 2012, new research funded by brand drug manufacturers shows.
The share of Part B drugs administered in
…
The 117th Congress appears destined to end without further action on the 340B program.
The House and Senate are on track to finish all work for the year by no later than Friday, Dec. 23. According to news reports yesterday,
…
The U.S. Health Resources and Services Administration has slightly adjusted the dates of the first of four periods in 2023 during which eligible entities may register themselves, their child sites, and their contract pharmacies to participate in the 340B program.
…
Biopharmaceutical manufacturer Biogen yesterday became the 19th prescription drug company to announce conditions on 340B pricing when covered entities contract with outside pharmacies.
Massachusetts-based Biogen posted a Dec. 12 letter to entities and an accompanying FAQ describing its new
…